drugset / Trial / NCT00777946

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

NCT00777946

Phase 3 Completed 818 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients not adequately controlled with aliskiren alone

Timeline

Start
2008-10
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aliskiren Small molecule 300 mg Oral
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Amlodipine Other / unclassified 10 mg Oral